Affiliation:
1. Central Laboratory of the Bacteriologic Infection Serology Study Group of Germany (BISSGG), Institute of Medical Microbiology, University Hospital of Frankfurt, Paul-Ehrlich-Str. 40, D-60596 Frankfurt/Main, Germany
Abstract
ABSTRACT
The accuracy of diagnostic tests is critical for successful control of epidemic outbreaks of syphilis. The reliability of syphilis serology in the nonspecialist laboratory has always been questioned, but actual data dealing with this issue are sparse. Here, the results of eight proficiency testing sentinel surveys for diagnostic laboratories in Germany between 2000 and 2003 were analyzed. Screening tests such as
Treponema pallidum
hemagglutination assay (mean accuracy, 91.4% [qualitative], 75.4% [quantitative]),
Treponema pallidum
particle agglutination assay (mean accuracy, 98.1% [qualitative], 82.9% [quantitative]), and enzyme-linked immunosorbent assays (ELISAs) (mean qualitative accuracy, 95%) were more reliable than Venereal Disease Research Laboratory (VDRL) testing (mean accuracy, 89.6% [qualitative], 71.1% [quantitative]), the fluorescent treponemal antibody absorption test (FTA-ABS) (mean accuracy, 88% [qualitative], 65.8% [quantitative]), and immunoblot assays (mean qualitative accuracy, 87.3%). Clearly, immunoglobulin M (IgM) tests were more difficult to manage than IgG tests. False-negative results for samples that have been unambiguously determined to be IgM and anti-lipoid antibody positive accounted for 4.7% of results in the IgM ELISA, 6.9% in the VDRL test, 18.5% in the IgM FTA-ABS, and 23.0% in the IgM immunoblot assay. For negative samples, the mean percentage of false-positive results was 4.1% in the VDRL test, 5.4% in the IgM ELISA, 0.7% in the IgM FTA-ABS, and 1.4% in the IgM immunoblot assay. On average, 18.3% of participants misclassified samples from patients with active syphilis as past infection without indicating the need for further treatment. Moreover, 10.2% of laboratories wrongly reported serological evidence for active infection in samples from patients with past syphilis or in sera from seronegative blood donors. Consequently, the continuous participation of laboratories in proficiency testing and further standardization of tests is strongly recommended to achieve better quality of syphilis serology.
Publisher
American Society for Microbiology
Reference22 articles.
1. Bundesministerium fuer Gesundheit (BMFG). 2000. Bekanntmachung (AKZ 117-456000-02/2) zur EG-Richtlinie über in vitro Diagnostika (98/79/EG). Bundesgesetzblatt 118 : 12077.
2. Center for Disease Control. 1977. Guidelines for evaluation and acceptance of new syphilis serology tests for routine use. Center for Disease Control Atlanta Ga.
3. Centers for Disease Control and Prevention and Association of State and Territorial Public Health Laboratory Directors (ASTPHLD). 1994. Proceedings of the 2nd National Conference on Serologic Diagnosis of Lyme Disease (Dearborn MI). ASTPHLD Washington D.C.
4. Centers for Disease Control and Prevention. 2002. Sexually transmitted diseases treatment guidelines 2002. Morb. Mortal. Wkly. Rep.51:1-80. [Online.] http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5106a1.htm . Accessed 1 December 2005.
5. Centers for Disease Control and Prevention. 2003. Primary and secondary syphilis—United States, 2002. Morb. Mortal. Wkly. Rep.52:1117-1120.
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献